CoChat

Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer

Open access
Li, Qiong, Zhang, Daoxiang, Chen, Xiaoying, He, Lei, Li, Tianming, Xu, Xiaoping, Li, Min · 2015 · Scientific Reports

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Gefitinib (Iressa, ZD-1839), a small molecule tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) pathway, is currently under investigation in clinical trials for the treatment of colorectal cancer (CRC). However, as known, some patients develop resistance to TKIs and the mechanisms mediating intrinsic resistance to EGFR-TKIs in CRC have not been fully characterized. Resistance to EGFR inhibitors reportedly involves activation of signal transducer and activator of transcription 3 (STAT3) in glioma and lung cancer. Here, we demonstrated that the nuclear pyruvate kinase isoform M2 (PKM2) levels were positively correlated with gefitinib resistance in CRC cells. The overexpression of nuclear PKM2 in HT29 cells decreased the effect of gefitinib therapy, whereas PKM2 knockdown increased gefitinib efficacy. Furthermore, the activation of STAT3 by nuclear PKM2 was associated with gefitinib resistance. Inhibition of STAT3 by Stattic, a STAT3-specific inhibitor, or STAT3-specific siRNA sensitized resistant cells to gefitinib. These results suggest that nuclear PKM2 modulates the sensitivity of CRC cells to gefitinib and indicate that small molecule pharmacological disruption of nuclear PKM2 association with STAT3 is a potential avenue for overcoming EGFR-TKI resistance in CRC patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep16082

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Nuclear PKM2 expression in CRC cell lines correlates with their resistance to gefitinib. (A) Representative CRC cell lines were treated with varying concentrations of gefitinib. MTS assays were conducted, and IC50 values were calculated after 72 h (*P < 0.05, **P < 0.01). (B) The expression of PKM2, phosphorylation and total EGFR were detected in nuclear extracts (NE) and cytoplasmic extracts (Cyto) of three representative CRC cell lines using Western blot analysis. Lamin B or β-actin were loading controls. GAPDH in nuclear extracts was analyzed as a control showing there were no cytoplasmic protein contaminations. (C) The protein levels of nuclear PKM2 were quantified by densitometry analysis, and the reading was normalized to Lamin B. The error bars represent the S.D. of the mean values of three experiments. A Student’s t-test was used to assess the significance of the differences in the nuclear PKM2 between the cells lines. (D) The association between nuclear PKM2 protein expression levels and gefitinib sensitivity of CRC cells was evaluated using Pearson analysis. The coefficient of determination (R2) in the linear regression model was calculated. (E,G) The expression of PKM2 in HT29 (E) and C2BBel (G) cells were analyzed by immunoblot of nuclear extracts (NE) and whole-cell lysates (WCL) of cells in which nuclear PKM2 was overexpressed or knocked down. (F,H) The viability was analyzed using the MTS assays in HT29 (F) and C2BBel (H) cells treated with different concentrations of gefitinib. Nuclear PKM2 was overexpressed or knocked down in HT29 (F) and C2BBel (H) cells, respectively.
Figure 1 Nuclear PKM2 expression in CRC cell lines correlates with their resistance to gefitinib. (A) Representative CRC cell lines were treated with varying concentrations of gefitinib. MTS assays were conducted, and IC50 values were calculated after 72 h (*P < 0.05, **P < 0.01). (B) The expression of PKM2, phosphorylation and total EGFR were detected in nuclear extracts (NE) and cytoplasmic extracts (Cyto) of three representative CRC cell lines using Western blot analysis. Lamin B or β-actin were loading controls. GAPDH in nuclear extracts was analyzed as a control showing there were no cytoplasmic protein contaminations. (C) The protein levels of nuclear PKM2 were quantified by densitometry analysis, and the reading was normalized to Lamin B. The error bars represent the S.D. of the mean values of three experiments. A Student’s t-test was used to assess the significance of the differences in the nuclear PKM2 between the cells lines. (D) The association between nuclear PKM2 protein expression levels and gefitinib sensitivity of CRC cells was evaluated using Pearson analysis. The coefficient of determination (R2) in the linear regression model was calculated. (E,G) The expression of PKM2 in HT29 (E) and C2BBel (G) cells were analyzed by immunoblot of nuclear extracts (NE) and whole-cell lysates (WCL) of cells in which nuclear PKM2 was overexpressed or knocked down. (F,H) The viability was analyzed using the MTS assays in HT29 (F) and C2BBel (H) cells treated with different concentrations of gefitinib. Nuclear PKM2 was overexpressed or knocked down in HT29 (F) and C2BBel (H) cells, respectively.CC BY · PubMed Central
Figure 2 The overexpression of nuclear PKM2 suppresses the apoptosis and cell cycle arrest of CRC cells induced by gefitinib. (A,C) Flow cytometry was used to analyze the annexin V-positive population of HT29 or C2BBel cells. The final concentration of gefitinib was 10 μM or 30 μM. (B,D) Cleaved PARP and caspase-3 were detected with Western blotting in HT29 or C2BBel cells, which were transfected with PKM2-NLS or PKM2 shRNA. (E,G) Flow cytometry was used to detect the proportions of cells in G1, S and G2-M phases. The final concentration of gefitinib was 10 μM or 30 μM. (F,H) Cyclin D1 and p27Kip1 were detected with Western blotting in HT29 or C2BBel cells, which were transfected with PKM2-NLS or PKM2 shRNA.
Figure 2 The overexpression of nuclear PKM2 suppresses the apoptosis and cell cycle arrest of CRC cells induced by gefitinib. (A,C) Flow cytometry was used to analyze the annexin V-positive population of HT29 or C2BBel cells. The final concentration of gefitinib was 10 μM or 30 μM. (B,D) Cleaved PARP and caspase-3 were detected with Western blotting in HT29 or C2BBel cells, which were transfected with PKM2-NLS or PKM2 shRNA. (E,G) Flow cytometry was used to detect the proportions of cells in G1, S and G2-M phases. The final concentration of gefitinib was 10 μM or 30 μM. (F,H) Cyclin D1 and p27Kip1 were detected with Western blotting in HT29 or C2BBel cells, which were transfected with PKM2-NLS or PKM2 shRNA.CC BY · PubMed Central
Figure 3 Nuclear PKM2-induced STAT3 phosphorylation correlates with gefitinib resistance in CRC cells. (A) Representative CRC cell lines were treated with gefitnib or left untreated. At 48 h after treatment, the cells were lysed and subjected to immunoblot analysis. The levels of phosphorylated and total STAT3 in nuclear extracts (NE) and whole-cell lysates (WCL) were detected. (B) Total and phosphorylated STAT3 were detected with Western blotting in HT29 or C2BBel cells, which were transfected with PKM2-NLS or PKM2 shRNA, respectively. (C) STAT3 phosphorylation was regulated by nuclear PKM2 through physical binding. The left panel shows Western blotting results of STAT3 after PKM2 immunoprecipitation (IP); the middle and right panel shows Western blot results for the reciprocal IP and loading control. (D) Phosphorylation of endogenous STAT3 (IP: STAT3) or exogenously expressed mutant Y705A (IP: Flag) by PKM2 in SW480 cell nucleus was analyzed by immunoprecipitation using anti-STAT3 antibody (IP: STAT3) or anti-Flag antibody (IP: Flag) followed by immunoblot using antibody against phospho-tyrosine (IB: pTy-100).
Figure 3 Nuclear PKM2-induced STAT3 phosphorylation correlates with gefitinib resistance in CRC cells. (A) Representative CRC cell lines were treated with gefitnib or left untreated. At 48 h after treatment, the cells were lysed and subjected to immunoblot analysis. The levels of phosphorylated and total STAT3 in nuclear extracts (NE) and whole-cell lysates (WCL) were detected. (B) Total and phosphorylated STAT3 were detected with Western blotting in HT29 or C2BBel cells, which were transfected with PKM2-NLS or PKM2 shRNA, respectively. (C) STAT3 phosphorylation was regulated by nuclear PKM2 through physical binding. The left panel shows Western blotting results of STAT3 after PKM2 immunoprecipitation (IP); the middle and right panel shows Western blot results for the reciprocal IP and loading control. (D) Phosphorylation of endogenous STAT3 (IP: STAT3) or exogenously expressed mutant Y705A (IP: Flag) by PKM2 in SW480 cell nucleus was analyzed by immunoprecipitation using anti-STAT3 antibody (IP: STAT3) or anti-Flag antibody (IP: Flag) followed by immunoblot using antibody against phospho-tyrosine (IB: pTy-100).CC BY · PubMed Central
Figure 4 Nuclear PKM2-induced gefitinib resistance is mediated by STAT3. (A) STAT3 was knocked down in HT29/PKM2-NLS cells by siRNA (50 nM final concentration for both STAT3-specific and negative control siRNA). (B) STAT3 siRNA reinstated gefitinib sensitivity of HT29/PKM2-NLS cells. The indicated cells lines were treated with gefitinib for three days, which was followed by an MTS assay, at two days after transfection. (C) Cleaved PARP and caspase-3 were detected with Western blotting in HT29/PKM2-NLS cells, which were transfected with STAT3 siRNA. (D) Flow cytometry was used to analyze the annexin V-positive population of HT29/PKM2-NLS cells. The final concentration of gefitinib was 10 μM. (E) Western blot analysis was employed to detect the expression level of cyclin D1 and p27kip1 in HT29/PKM2-NLS cells, which were transfected with STAT3 siRNA. (F) The proportions of cells in the different phases were quantified using flow cytometry. The final concentration of gefitinib was 10 μM.
Figure 4 Nuclear PKM2-induced gefitinib resistance is mediated by STAT3. (A) STAT3 was knocked down in HT29/PKM2-NLS cells by siRNA (50 nM final concentration for both STAT3-specific and negative control siRNA). (B) STAT3 siRNA reinstated gefitinib sensitivity of HT29/PKM2-NLS cells. The indicated cells lines were treated with gefitinib for three days, which was followed by an MTS assay, at two days after transfection. (C) Cleaved PARP and caspase-3 were detected with Western blotting in HT29/PKM2-NLS cells, which were transfected with STAT3 siRNA. (D) Flow cytometry was used to analyze the annexin V-positive population of HT29/PKM2-NLS cells. The final concentration of gefitinib was 10 μM. (E) Western blot analysis was employed to detect the expression level of cyclin D1 and p27kip1 in HT29/PKM2-NLS cells, which were transfected with STAT3 siRNA. (F) The proportions of cells in the different phases were quantified using flow cytometry. The final concentration of gefitinib was 10 μM.CC BY · PubMed Central
Figure 5 Nuclear PKM2 decreases the sensitivity of CRC cells to gefitinib in vivo. (A,B) The tumor images from the nuclear PKM2 overexpression, PKM2 knockdown, or the control group were determined at the 28th day with or without gefitinib treatment (50 mg/kg/day), and the tumor growth rate were analyzed between the groups. (C) Stattic sensitized HT29/PKM2-NLS cells to gefitinib in vivo. Mice were subcutaneously implanted with HT29/PKM2-NLS cell lines. Mice were administrated with vehicle (saline), Stattic at 10 mg/kg/day, gefitinib at 50 mg/kg/day, or the combination of the 2 drugs for 4 weeks. (D) The TUNEL-positive cells were analyzed in the tumor sections. We counted the number of nuclei that were positively stained to determine the percentage of TUNEL-positive cells in the groups, using three randomly selected fields in each slide. (E) The Ki67-positive cells were analyzed in the tumor sections; the percentage of Ki67-positive cells in the groups was counted.
Figure 5 Nuclear PKM2 decreases the sensitivity of CRC cells to gefitinib in vivo. (A,B) The tumor images from the nuclear PKM2 overexpression, PKM2 knockdown, or the control group were determined at the 28th day with or without gefitinib treatment (50 mg/kg/day), and the tumor growth rate were analyzed between the groups. (C) Stattic sensitized HT29/PKM2-NLS cells to gefitinib in vivo. Mice were subcutaneously implanted with HT29/PKM2-NLS cell lines. Mice were administrated with vehicle (saline), Stattic at 10 mg/kg/day, gefitinib at 50 mg/kg/day, or the combination of the 2 drugs for 4 weeks. (D) The TUNEL-positive cells were analyzed in the tumor sections. We counted the number of nuclei that were positively stained to determine the percentage of TUNEL-positive cells in the groups, using three randomly selected fields in each slide. (E) The Ki67-positive cells were analyzed in the tumor sections; the percentage of Ki67-positive cells in the groups was counted.CC BY · PubMed Central
Figure 6 Schema illustrating the mechanism of nuclear PKM2-regulated resistance to gefitinib in CRC. This figure was drawn by Q.L.
Figure 6 Schema illustrating the mechanism of nuclear PKM2-regulated resistance to gefitinib in CRC. This figure was drawn by Q.L.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 116

Metadata

Authors
Li, Q., Zhang, D., Chen, X., He, L., Li, T., Xu, X., & Li, M.
Affiliations
  • Shanghai Jiao Tong University (CN)
  • Washington University in St. Louis (US)
Corresponding author
Li, Min
Venue
Scientific Reports
Published
2015-11-06
Volume
5
Issue
1
Pages
16082-16082
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2195075045
Cited by
114
References
32
Citations by year
2026: 5 · 2025: 8 · 2024: 7 · 2023: 14 · 2022: 9 · 2021: 15 · 2020: 13 · 2019: 15 · 2018: 12 · 2017: 12 · 2016: 4
FWCI
4.08
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (81322025, 81401735, #81421001, 81371875)
  • Foundation for Innovative Research Groups of the National Natural Science Foundation of China (81421001)
  • Renji Hospital
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
gefitinib resistance, STAT3 activation, colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Stattic, STAT3 inhibition, tumor suppressor gene reactivation, drug resistance mechanisms
MeSH terms
Gefitinib, Thyroid Hormone-Binding Proteins, Antineoplastic Agents, Carrier Proteins, Cell Line, Cell Nucleus, Humans, Membrane Proteins, Quinazolines, Thyroid Hormones, Colorectal Neoplasms, Transcriptional Activation, Up-Regulation, Drug Resistance, Neoplasm, HT29 Cells, HCT116 Cells, Cell Line, Tumor, Protein Kinase Inhibitors, STAT3 Transcription Factor, HEK293 Cells, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.